Effect of nitric oxide on the anticancer activity of the topoisomerase-active drugs etoposide and adriamycin in human melanoma cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 347, Issue 3, 2013, Pages 607-614

  Sinha, Birandra K ^a   Kumar, Ashutosh ^a   Bhattacharjee, Suchandra ^a   Espey, Michael G ^b   Mason, Ronald P ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; DOXORUBICIN; ETOPOSIDE; N6 (1 IMINOETHYL)LYSINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROGEN OXIDE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG DETOXIFICATION; DRUG INTERACTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MACROPHAGE; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; DNA TOPOISOMERASES; DOXORUBICIN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME INHIBITORS; ETOPOSIDE; HUMANS; LYSINE; MACROPHAGES; MELANOMA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

EID: 84887979825     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.207928     Document Type: Article

References (59)

1. Alley MC, Scudiero DA, Monks A, Hursey M.L., Czerwinski MJ, Fine DL, Abbott BJ, Mayo J.G., Shoemaker RH, and Boyd MR (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:589-601. (Pubitemid 18056527)
2. Ambs S and Glynn SA (2011) Candidate pathways linking inducible nitric oxide synthase to a basal-like transcription pattern and tumor progression in human breast cancer. Cell Cycle 10:619-624.
3. Chatterjee S, Lardinois O, Bonini M.G., Bhattacharjee S., Stadler K, Corbett J, Deterding L.J., Tomer KB, Kadiiska M, and Mason RP (2009) Site-specific car-boxypeptidase B1 tyrosine nitration and pathophysiological implications following its physical association with nitric oxide synthase-3 in experimental sepsis. J Immunol 183:4055-4066.
4. Chanvorachote P, Nimmannit U, Stehlik C., Wang L, Jiang BH, Ongpipatanakul B, and Rojanasakul Y (2006) Nitric oxide regulates cell sensitivity to cisplatin-induced apoptosis through S-nitrosylation and inhibition of Bcl-2 ubiquitination. Cancer Res 66:6353-6360.
5. Chen GG, Lee TW, Xu H, Yip JHY, Li M, Mok TSK, and Yim AP (2008) Increased inducible nitric oxide synthase in lung carcinoma of smokers. Cancer 112:372-381.
6. Chin MP and Deen WM (2010) Prediction of nitric oxide concentrations in melanoma. Nitric Oxide 23:319-326.
7. Cook JA, Krishna MC, Pacelli R, DeGraff W., Liebmann J, Mitchell JB, Russo A, and Wink DA (1997) Nitric oxide enhancement of melphalan-induced cytotoxicity. Br J Cancer 76:325-334. (Pubitemid 27308082)
8. Cudic M and Ducrocq C (2000) Transformations of 2, 6-diisopropylphenol by NO-derived nitrogen oxides, particularly peroxynitrite. Nitric Oxide 4:147-156. (Pubitemid 30318305)
9. Curtis JF, Reddy NG, Mason R.P., Kalyanaraman B., and Eling TE (1996) Nitric oxide: a prostaglandin H synthase 1 and 2 reducing cosubstrate that does not stimulate cyclooxygenase activity or prostaglandin H synthase expression in murine mac-rophages. Arch Biochem Biophys 335:369-376. (Pubitemid 26384803)
10. Doroshow JH (1983) Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Cancer Res 43: 4543-4551. (Pubitemid 13014179)
11. Espey MG, Miranda KM, Thomas D.D., and Wink DA (2001) Distinction between nitrosating mechanisms within human cells and aqueous solution. J Biol Chem 276:30085-30091.
12. Evig CB, Kelley EE, Weydert C.J., Chu Y., Buettner GR, and Burns CP (2004) Endogenous production and exogenous exposure to nitric oxide augment doxorubicin cy-totoxicity for breast cancer cells but not cardiac myoblasts. Nitric Oxide 10:119-129. (Pubitemid 38668661)
13. Fan Y, Schreiber EM, Giorgianni A, Yalowich J.C., and Day BW (2006) Myeloperoxidase-catalyzed metabolism of etoposide to its quinone and glutathione adduct forms in HL60 cells. Chem Res Toxicol 19:937-943. (Pubitemid 44092360)
14. Gantchev TG and Hunting DJ (1998) The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II/DNA cleavable complex. Mol Pharmacol 53:422-428. (Pubitemid 28162863)
15. Glisson B, Gupta R, Smallwood-Kentro S, and Ross WE (1986) Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity. Cancer Res 46:1934-1938. (Pubitemid 16117888)
16. *NO2 and peroxynitrite in membranes: physiological implications. Free Radic Res 31: 597-606.
17. Grimm EA, Ellerhorst J, Tang C.H., and Ekmekcioglu S (2008) Constitutive in-tracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis. Nitric Oxide 19:133-137.
18. Haim N, Roman J, Nemec J., and Sinha BK (1986) Peroxidative free radical formation and O-demethylation of etoposide (VP-16) and teniposide (VM-26). Biochem Bio-phys Res Commun 135:215-220. (Pubitemid 16063992)
19. Haim N, Nemec J, Roman J., and Sinha BK (1987a) In vitro metabolism of etoposide (VP-16-213) by liver microsomes and irreversible binding of reactive intermediates to microsomal proteins. Biochem Pharmacol 36:527-536. (Pubitemid 17024178)
20. Haim N, Nemec J, Roman J., and Sinha BK (1987b) Peroxidase-catalyzed metabolism of etoposide (VP-16-213) and covalent binding of reactive intermediates to cellular macromolecules. Cancer Res 47:5835-5840. (Pubitemid 18018715)
21. Henwood JM and Brogden RN (1990) Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs 39:438-490.
22. Hickok JR and Thomas DD (2010) Nitric oxide and cancer therapy: the emperor has NO clothes. Curr Pharm Des 16:381-391.
23. Hogg N, Singh RJ, Goss SPA, and Kalyanaraman B (1996) The reaction between nitric oxide and alpha-tocopherol: a reappraisal. Biochem Biophys Res Commun 224:696-702. (Pubitemid 26278648)
24. Jenkins DC, Charles IG, Thomsen L.L., Moss DW, Holmes LS, Baylis SA, Rhodes P, Westmore K., Emson PC, and Moncada S (1995) Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 92:4392-4396.
25. Janzen EG, Wilcox AL, and Manoharan V (1993) Reactions of nitric oxide with phenolic antioxidants and phenoxyl radicals. J Org Chem 58:3597-3599 DOI: 10.1021/jo00066a001.
26. Kagan VE, Kuzmenko AI, Tyurina Y.Y., Shvedova AA, Matsura T, and Yalowich JC (2001) Pro-oxidant and antioxidant mechanisms of etoposide in HL-60 cells: role of myeloperoxidase. Cancer Res 61:7777-7784. (Pubitemid 33049364)
27. Kalyanaraman B, Perez-Reyes E, and Mason RP (1980) Spin-trapping and direct electron spin resonance investigations of the redox metabolism of quinone anti-cancer drugs. Biochim Biophys Acta 630:119-130. (Pubitemid 10019440)
28. Kalyanaraman B, Nemec J, and Sinha BK (1989) Characterization of free radicals produced during oxidation of etoposide (VP-16) and its catechol and quinone derivatives. An ESR Study. Biochemistry 28:4839-4846. (Pubitemid 19151065)
29. Katki AG, Kalyanaraman B, and Sinha BK (1987) Interactions of the antitumor drug, etoposide, with reduced thiols in vitro and in vivo. Chem Biol Interact 62:237-247. (Pubitemid 17142336)
30. Lewis CE and Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66:605-612. (Pubitemid 43165918)
31. Lepoivre M, Flaman JM, Bobé P, Lemaire G, and Henry Y (1994) Quenching of the tyrosyl free radical of ribonucleotide reductase by nitric oxide. Relationship to cytostasis induced in tumor cells by cytotoxic macrophages. J Biol Chem 269: 21891-21897. (Pubitemid 24274834)
32. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58:351-375. (Pubitemid 19172974)
33. Liu LF, Rowe TC, Yang L, Tewey K.M., and Chen GL (1983) Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem 258:15365-15370.
34. Liu X, Miller MJ, Joshi M.S., Thomas DD, and Lancaster JR, Jr (1998) Accelerated reaction of nitric oxide with O2 within the hydrophobic interior of biological membranes. Proc Natl Acad Sci USA 95:2175-2179. (Pubitemid 28145914)
35. Loike JD and Horwitz SB (1976) Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells. Biochemistry 15:5443-5448. (Pubitemid 8004252)
36. Long BH, Musial ST, and Brattain MG (1984) Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship. Biochemistry 23:1183-1188. (Pubitemid 14174513)
37. Lovett BD, Strumberg D, Blair I.A., Pang SK, Burden DA, Megonigal MD, Rappaport E.F., Rebbeck TR, Osheroff N, and Pommier YG, et al (2001) Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints. Biochemistry 40:1159-1170. (Pubitemid 32142877)
38. Miersch S, Espey MG, Chaube R, Akarca A., Tweten R, Ananvoranich S, and Mutus B (2008) Plasma membrane cholesterol content affects nitric oxide diffusion dynamics and signaling. J Biol Chem 283:18513-18521.
39. 2 reaction. Chem Res Toxicol 20:709-714. (Pubitemid 46762106)
40. Myers CE, Mimnuagh E, Yeh G., and Sinha BK (1987) Biochemical Mechanism of Tumor Cell Kill by the Anthracyclines in Anthracyclines and Anthracenedione-Based Anticancer Agents (Lown W, ed) pp 527-569, Elsevier, NY.
41. Pollard JW (2008) Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 84:623-630.
42. Rajagopalan S, Politi PM, Sinha B.K., and Myers CE (1988) Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res 48:4766-4769.
43. Ranguelova K, Suarez J, Magliozzo R.S., and Mason RP (2008) Spin trapping investigation of peroxide- and isoniazid-induced radicals in Mycobacterium tuberculosis catalase-peroxidase. Biochemistry 47:11377-11385.
44. Sikora AG, Gelbard A, Davies M.A., Sano D., Ekmekcioglu S, Kwon J, Hailemichael Y., Jayaraman P, Myers JN, and Grimm EA, et al. (2010) Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res 16:1834-1844.
45. Sinha BK (1995) Topoisomerase inhibitors: therapeutic potentials. Drugs 49:11-19.
46. Sinha BK, Politi PM, Eliot H.M., Kerrigan D., and Pommier Y (1990) Structure-activity relations, cytotoxicity and topoisomerase II dependent cleavage induced by pendulum ring analogues of etoposide. Eur J Cancer 26:590-593. (Pubitemid 20259336)
47. Sinha BK (1980) Binding specificity of chemically and enzymatically activated anthracycline anticancer agents to nucleic acids. Chem Biol Interact 30:67-77. (Pubitemid 10134360)
48. Sinha BK, Trush MA, Kennedy K.A., and Mimnaugh EG (1984) Enzymatic activation and binding of adriamycin to nuclear DNA. Cancer Res 44:2892-2896. (Pubitemid 14083255)
49. Sinha BK, Katki AG, Batist G, Cowan K.H., and Myers CE (1987) Differential formation of hydroxyl radicals by Adriamycin in sensitive and resistant MCF-7 human breast tumor cells: implications for the mechanism of action. Biochemistry 26:3776-3781. (Pubitemid 17127450)
50. Sinha BK, Haim N, Dusre L., Kerrigan D, and Pommier Y (1988) DNA strand breaks produced by etoposide (VP-16, 213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action. Cancer Res 48:5096-5100.
51. Sinha BK, Bhattacharjee S, Chatterjee S., Jiang JJ, Motten AG, Kumar A, Espey M.G., and Mason RP (2013) Role of nitric oxide in the chemistry and anticancer activity of etoposide (VP-16, 213). Chem Res Toxicol 26:379-387.
52. Tang CH and Grimm EA (2004) Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. J Biol Chem 279:288-298. (Pubitemid 38044827)
53. Wink DA, Cook JA, Christodoulou D, Krishna M.C., Pacelli R., Kim S, Degraff W, Gamsom J., Vodovotz Y, and Russo A, et al (1997) Nitric oxide and some NO donor compounds enhance the cytotoxicity of cisplatin. Nitric Oxide 1:88-94. (Pubitemid 28078131)
54. Wink DA, Vodovotz Y, Cook J.A., Krishna MC, Kim S, Coffin D, DeGraff W., Deluca AM, Liebmann J, and Mitchell JB (1998) The role of nitric oxide chemistry in cancer treatment. Biochemistry (Mosc) 63:802-809. (Pubitemid 128588109)
55. van Maanen JMS, de Vries J, Pappie D, van den Akker E, Lafleur VM, Retèl J, van der Greef J, and Pinedo HM (1987) Cytochrome P-450-mediated O-demethylation: a route in the metabolic activation of etoposide (VP-16-213). Cancer Res 47:4658-4662. (Pubitemid 17127419)
56. + cells. Mol Pharmacol 79:479-487.
57. Xu WM, Liu LZ, Loizidou M, Ahmed M., and Charles IG (2002) The role of nitric oxide in cancer. Cell Res 12:311-320. (Pubitemid 135708343)
58. Yenes S and Messeguer A (1999) A study of the reaction of different phenol substrates with nitric oxide and peroxynitrite. Tetrahedron 55:14111-14122 DOI: 10.1016/S0040-4020(99)00877-7.
59. Zhuang L, Lin JQ, Lu M.L., Solomon KR, and Freeman MR (2002) Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res 62: 2227-2231. (Pubitemid 34411694)